Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January–December 2021

The population in rural southwest Alaska has been disproportionately affected by COVID-19. To assess the benefit of COVID-19 vaccines, we analyzed data from the regional health system. We estimated vaccine effectiveness (VE) during January 16–December 3, 2021, against symptomatic SARS-CoV-2 infectio...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-05, Vol.41 (23), p.3544-3549
Main Authors: Lefferts, Brian, Bruden, Dana, Plumb, Ian D., Hodges, Ellen, Bates, Elizabeth, January, Gerald, Bruce, Michael G.
Format: Article
Language:English
Subjects:
Adult
Adults
Alaska - epidemiology
Alaska Native People
American Indian People
Antigens
Contact tracing
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 diagnostic tests
COVID-19 Vaccines
Effectiveness
Electronic health records
Health facilities
Health services utilization
Hospitalization
Human subjects
Humans
Immunization
Infections
Influenza
Review boards
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Towns
Vaccine Effectiveness
Vaccine efficacy
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The population in rural southwest Alaska has been disproportionately affected by COVID-19. To assess the benefit of COVID-19 vaccines, we analyzed data from the regional health system. We estimated vaccine effectiveness (VE) during January 16–December 3, 2021, against symptomatic SARS-CoV-2 infection after a primary series or booster dose, and overall VE against hospitalization. VE of a primary series against symptomatic infection among adult residents was 91.3% (95% CI: 85.7, 95.2) during January 16–May 7, 2021, 50.3% (95% CI, 41.1%–58.8%) during July 17–September 24, and 37.0% (95% CI, 27.8–45.0) during September 25–December 3, 2021; VE of a booster dose during September 25–December 3, 2021, was 92.1% (95% CI: 87.2–95.2). During the overall study period, VE against hospitalization was 91.9% (95% CI: 85.4–95.5). COVID-19 vaccination offered strong protection against hospitalization and a booster dose restored protection against symptomatic infection.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2023.04.070